Zoetis Inc. $ZTS Stock Position Reduced by Capital World Investors

Capital World Investors cut its stake in Zoetis Inc. (NYSE:ZTS) by 43.3% during the third quarter, HoldingsChannel reports. The fund owned 394,430 shares of the company’s stock after selling 300,957 shares during the quarter. Capital World Investors’ holdings in Zoetis were worth $57,711,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC raised its stake in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. Financial Consulate Inc. bought a new stake in shares of Zoetis in the 3rd quarter valued at approximately $39,000. SJS Investment Consulting Inc. increased its holdings in Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after buying an additional 257 shares during the last quarter. TruNorth Capital Management LLC bought a new position in Zoetis during the third quarter valued at approximately $42,000. Finally, Financial Gravity Companies Inc. acquired a new stake in Zoetis in the second quarter valued at approximately $47,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $115.25 on Friday. The firm has a market capitalization of $48.65 billion, a P/E ratio of 19.14, a P/E/G ratio of 1.83 and a beta of 0.95. The stock has a fifty day moving average price of $125.54 and a two-hundred day moving average price of $132.19. Zoetis Inc. has a 52-week low of $115.23 and a 52-week high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the previous year, the company earned $1.40 EPS. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s payout ratio is 35.22%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ZTS. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Bank of America lifted their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Stifel Nicolaus cut their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.